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Variation in the attachment of Streptococcus pneumoniae to human 
pharyngeal epithelial cells after treatment with S-carboxymethylcysteine
that is used in the treatment of different respiratory diseases 
characterized by abnormal mucus secretion. Noguchi3 ini-
tially demonstrated in clinical studies that the administra-
tion of S-CMC decreased the number of episodes of 
recurrent respiratory tract infections. Subsequently other 
studies showed its effectiveness in respiratory conditions as 
well as ear diseases.2,4,5 A series of studies demonstrated 
that S-CMC was able to decrease signifi cantly the attach-
ment of major respiratory bacteria such as Haemophilus 
infl uenzae, S. pneumoniae, and Moraxella catarrhalis to 
human pharyngeal epithelial cells (HPECs).6–8 This decrease 
in bacterial attachment results in a decrease in the occur-
rence of respiratory infections, because the attachment of 
bacteria to the host cell is responsible for the pathogenesis 
of respiratory infections. The decrease of attachment is 
explained by the fact that S-CMC can deplete carbohydrate 
structures on the cell surface and it can also alter the surface 
charge of cells.6,7
Although treatment of M. catarrhalis and non-typable H. 
infl uenzae with S-CMC has no effect on their attachment to 
HPECs, treatment of S. pneumoniae with this agent causes 
a signifi cant decrease in attachment ability, as shown in a 
study reported by Cakan at al.8 The mechanism of this effect 
is unknown. In the study of Cakan et al.,8 cells from one 
subject were used. Therefore, in the present study, we 
expanded our research to fi nd out whether this phenome-
non is affected by interindividual or interstrain variations. 
We found that there was interindividual or interstrain varia-
tion in the attachment inhibition exerted by S-CMC. In the 
present study we also tried to explore the possible mecha-
nism by which S-CMC can cause attachment inhibition. We 
found that attachment inhibition seemed to occur due to 
changes in the bacterial surface structure after treatment 
with S-CMC; however the inhibition of attachment did not 
alter the virulence of the bacteria.
The following strains of S. pneumoniae were used for 
attachment inhibition assays: strain SP-95-203 (minimum 
inhibitory concentration [MIC]: benzylpenicillin [PCG] 
0.05 μg/ml) of serotype 3; strain SP-02-26 (MIC: PCG 1 μg/
ml, mentioned previously as strain Y-21) of serotype 23F 
(originally isolated from a patient in Spain thought to be 
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Abstract S-carboxymethylcysteine (S-CMC) is a mucolytic 
agent that can prevent respiratory infection by decreasing 
the attachment of respiratory pathogens to human pharyn-
geal epithelial cells (HPECs). Streptococcus pneumoniae is 
a major cause of respiratory infections. A previous study 
revealed that treatment of S. pneumoniae with S-CMC 
caused a decrease in the attachment of this bacterium to 
HPECs. In the present study we found that the effect of 
S-CMC varied according to hosts and strains. S-CMC 
treatment altered the surface structure of S. pneumoniae, 
resulting in a decrease of attachment, without affecting the 
virulence of the bacteria.
Key words Streptococcus pneumoniae · S-carboxymethyl-
cysteine · Epithelial cells · Human
Streptococcus pneumoniae is a major pathogen in respira-
tory infections. Worldwide, the rise of antibiotic resistance 
to S. pneumoniae has made it diffi cult to treat S. pneu-
moniae infections with commonly used antibiotics.1 There-
fore, focus has been placed on the search for novel means 
of treatment which might avoid the risk of developing anti-
biotic resistance. S-carboxymethylcysteine (S-CMC) is a 
nonantibiotic drug which has the potential to be used to 
prevent respiratory infection.2 S-CMC is a mucolytic agent 
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responsible for the spread of penicillin-resistance in differ-
ent parts of the world);9 strain SP-01-291 (MIC: PCG 16 μg/
ml), and strain SP-01-292 (MIC: PCG 4 μg/ml) of serotype 
19F. All strains were isolated from the sputum of patients 
with respiratory infections. HPECs were obtained from 
three healthy volunteers; two females (subjects 2 and 3) and 
one male (subject 1) with an average age of 19 years. The 
attachment inhibition assay was performed as previously 
described.8 In the present study, 5% sheep blood agar 
(Columbia agar + 5% sheep blood; Biomerieux, Marcy 
l’Etoile, France) was used to grow S. pneumoniae. Bacteria 
and HPECs were treated with 10 μg/ml and 1 μg/ml of S-
CMC (Kyorin Pharmaceutical, Tokyo, Japan), respectively, 
and suspended in 1/15 mmol phosphate buffer (pH 7.2) for 
30 min at 37°C. In a previous study, it was reported that the 
peak serum level of S-CMC was 2.4–4.6 μg/ml, and this 
occurred 1.5–3.5 h after the oral administration of 500 mg 
S-CMC.6 In another study, after the oral administration of 
500 mg S-CMC three times daily for 7 days, the sputum 
level of S-CMC ranged from less than 0.1 to 2.0 μg/ml. 
Although these concentrations are compatible with using 
1 μg/ml of S-CMC, we took other factors into consideration 
to decide the concentration of S-CMC to be used in the 
present study. If S-CMC is used as an attachment inhibition 
agent it is not given orally but is delivered directly to the 
pharynx by spray or gargle; therefore, a higher drug con-
centration can be administered. We analyzed the data of 
our previous experiments and found that 10 and 1 μg/ml 
were the minimum concentrations at which attachment 
inhibition occurred in a consistent and signifi cant way, 
for bacteria and HPECs, respectively.6–8 As controls, 
untreated bacteria and HPECs were handled similarly to 
the treated bacteria and HPECs, without treatment with S-
CMC. The mean value of duplicate experiments was deter-
mined in each experiment. At least three experiments were 
done for each subject or strain. Compared with the control, 
a 50% decrease in mean bacterial attachment was consid-
ered as signifi cant.10 Our experiment showed that, com-
pared to the untreated control, there was no signifi cant 
change in the viability of S. pneumoniae after treatment 
with S-CMC. Gram staining showed that there was no sig-
nifi cant change in S-CMC-treated bacteria compared with 
the control.
To determine the effect of S-CMC on the surface mor-
phology of S. pneumoniae, electron microscopy was done 
after treating strain SP-95-198 with 10 and 100 μg/ml of S-
CMC for 30 min in a shaking water bath at 37°C. Our previ-
ous study showed that the changes that occur at these 
concentrations are suitable for observation by electron 
microscope.6 Similarly handled untreated bacteria were 
taken as controls. Bacteria were washed with 0.1 M cacodyl-
ate buffer containing 0.04% ruthenium red (RR). Then they 
were fi xed with 2% glutaraldehyde in 0.1 M cacodylate 
buffer containing 0.05% RR overnight. After post-fi xation 
with osmium tetroxide, the samples were embedded in 
Quetol 653 (Nishshin EM, Tokyo, Japan) according to a 
previously published report.11
The effects of S-CMC on bacterial virulence were vali-
dated by challenging mice with S. pneumoniae. Five-week-
old pathogen-free, female ICR mice (Shizuoka Agricultural 
Cooperation Association for Laboratory Animals, Shi-
zuoka, Japan) were used. The mice were housed in clean 
conditions and were given sterile food and water. The mice 
were anesthetized by chloroform inhalation. Groups of fi ve 
mice were challenged intraperitoneally with S-CMC (10 μg/
ml)-treated bacterial suspensions in sterile phosphate-
buffered saline (PBS), with a concentration of 5 × 107 cfu/ml 
in an inoculum volume of 0.5 ml. Control mice were chal-
lenged with bacteria not treated with S-CMC. Mortality was 
determined every 24 h.
The attachment inhibition assay after bacteria were 
treated with S-CMC (Fig. 1) showed that, in subject 1, the 
attachment (expressed as percentage of the control [mean 
± SD]) of strains SP-01-291, SP-01-292, SP-02-26, and SP-
95-203 was 33.7 ± 13.3%, 44.1 ± 16.3%, 28.6 ± 21.1%, and 
40.9 ± 10.1%, respectively. In subject 2, the attachment of 
strains SP-01-291, SP-01-292, SP-02-26, and SP-95-203 was 
51.4 ± 21.7%, 57.1 ± 16.4%, 35.5 ± 17.3%, and 22.4 ± 17.3% 
of the control, respectively. In subject 3, the attachment of 
strains SP-01-291, SP-01-292, SP-02-26, and SP-95-203 was 
45.9 ± 10.6%, 46.1 ± 23.1%, 73.8 ± 5.1%, and 35.2 ± 18.2% 
of the control, respectively.
Except for SP-01-291 and SP-01-292 with the HPECs 
from subject 2 and SP-02-26 with the HPECs from subject 
3, all experiments showed there was a signifi cant decrease 
of attachment after the S. pneumoniae were treated with 
S-CMC. The attachment inhibition assay after HPECs were 
treated with S-CMC (Fig. 2) showed that in subject 1, the 
attachment of strains, SP-01-291, SP-01-292, SP-02-26, and 
SP-95-203 was 23.8 ± 23.1%, 13.4 ± 8.6%, 25.8 ± 9.2%, and 
22.0 ± 33.7% of the control, respectively. In subject 2, the 
attachment of strains SP-01-291, SP-01-292, SP-02-26, and 
SP-95-203 was 52.3 ± 36.2%, 32.8 ± 18.2%, 31.4 ± 24.9%, 
and 29.7 ± 10.2% of the control, respectively. In subject 3, 
the attachment of strains SP-01-291, SP-01-292, SP-02-26, 













































Fig. 1. Results of attachment inhibition assay after strains of Strepto-
coccus pneumoniae were treated with 10 μg/ml of S-carboxymethylcys-
teine (S-CMC). The names of the strains of S. pneumoniae are shown 
on the X-axis. The Y-axis indicates the attachment of bacteria per 
number of epithelial cells, expressed as percentages of the respective 
controls. In each experiment, the attachment assay was done in dupli-
cate and three experiments were done to determine the attachment of 
bacteria. Striped bars, Subject 1; black bars, subject 2; white bars, 
subject 3
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and SP-95-203 was 26.6 ± 15.0%, 25.0 ± 31.2%, 32.1 ± 40.4%, 
and 82.9 ± 77.6% of the control, respectively. Except for 
SP-01-291 with the HPECs from subject 2 and SP-95-203 
with the HPECs from subject 3, all experiments showed a 
signifi cant decrease of bacterial attachment to the HPECs. 
The attachment of S. pneumoniae to HPECs treated with 
S-CMC showed a greater decrease compared with the 
results of the attachment inhibition assay of bacteria treated 
with S-CMC (Fig. 1). The differences found in each experi-
ment after S-CMC treatment were due to interstrain and 
intersubject variations in the expression of adhesins and 
receptors on bacteria and HPECs, respectively.
As observed by electron microscopy, the surface in the 
untreated control bacteria appeared to be smooth (Fig. 3a). 
On the other hand, the surface became electron-dense after 
treatment with 10 μg/ml of S-CMC (Fig. 3b). This change 
was more evident in bacteria treated with 100 μg/ml of S-
CMC (Fig. 3c).
The virulence test showed that all mice died within 24 h 
and, therefore, compared to the untreated control, there 
was no change of virulence of S. pneumoniae, although the 
attachment to the cells was decreased after treatment with 
S-CMC.
The adherence of S. pneumoniae to eukaryotic cells is 
the initial step in the colonization and infection of the host.12 
Cell-wall proteins such as choline-binding proteins and 
peptide permeases have been reported to act as adhes-
ins.13–15 The bacterial capsule may function as an adhesin 
and enhance pneumococcal colonization.16,17 S. pneumoniae 
is capable of expressing a repertoire of at least 90 unique 
capsular polysaccharide types.18 Each of these polysaccha-
rides differs in the composition and linkage of its compo-
nent sugars as well as other substitutes.17 Other than these 
structures, surface charge also infl uences the attachment of 
bacteria to host epithelial cells.
The present study showed that S-CMC was able to inhibit 
the attachment of different strains of S. pneumoniae to 
HPECs from different individuals. However, the decrease 











































Fig. 2. Results of attachment inhibition assay after human pharyngeal 
epithelial cells (HPECs) were treated with 1 μg/ml of S-CMC. The 
names of the strains of S. pneumoniae are shown on the X-axis. The 
Y-axis indicates the attachment of bacteria per numbers of epithelial 
cells expressed as percentages of the respective controls. In each exper-
iment, the attachment assay was done in duplicate and three experi-
ments were done to determine the attachment of bacteria. Striped bars, 




Fig. 3a–c. Transmission electron microscope photographs of S. pneu-
moniae, showing the difference between bacteria treated with S-CMC 
and the untreated control. a In the untreated control, S. pneumoniae 
is observed to have a smooth surface. After treatment with S-CMC (b, 
c), the bacterial surface showed a granular structure, which was more 
apparent after treatment with 100 μg/ml of S-CMC (c) than after treat-
ment with 10 μg/ml of this agent (b). Bars, 400 nm
of attachment was not signifi cant in all cases. Therefore, it 
appears that strains of S. pneumoniae may differ in their 
attachment abilities and may respond differently to 
attachment-modulating agents. This study revealed that 
there were changes on the surface of S. pneumoniae after 
treatment with S-CMC. However, further study should be 
done to confi rm the electron-dense particles seen on the 
surface of S. pneumoniae after treatment with S-CMC.
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Of note, the changes on the surface of S. pneumoniae did 
not affect the virulence of the bacteria, as revealed by the 
mouse experiment. Thus, the virulence test in mice added 
further knowledge regarding the mechanism of action of 
S-CMC in vivo. The decrease of attachment after S-CMC 
treatment was not due to bactericidal effects, as our quan-
titative culture assay showed that S-CMC had no effect on 
the viability of the bacteria. This confi rms the results of our 
previous study.8 There is a range of interindividual variation 
in patients treated with S-CMC.19 Metabolism was impli-
cated as a major factor infl uencing the effi cacy of S-CMC. 
The present study has clarifi ed other important factors that 
may infl uence the effi cacy of S-CMC, such as the character-
istics of the bacterial and host cells which express different 
surface components.
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